Bristol-myers Squibb Compnay

Sandra V Hatcher

Alan J Korman

Mohan Srinivasan

Nils Lonberg

Aaron Paul Yamniuk

Karla Ann Henning

Bryan C Barnhart

Ming Lei

Liang Schweizer

Haichun Huang

Guodong Chen

Richard Y Huang

Maria N Jure-Kunkel

Martin J Corbett

John S Sack

Emanuela Sega

Angela Goodenough

Joseph E Myers, Jr

Pingping Zhang

Mark J Selby

Arvind Rajpal

Kent B Thudium

Changyu Wang

Han Chang

Mark F Maurer

Xi-Tao Wang

Michelle Minhua Han

Indrani Chakraborty

Brenda L Stevens

Jochem Gokemeijer

Huiming Li

Alexander T Kozhich

Thomas D Kempe

Michael Quigley

Susan Chien-Szu Wong

Xiang Shao

Hadia Lemar

Marie-Michelle Navarro Garcia

Christina Maria Milburn

Patrick Guirnalda

Zhehong Cai

Zheng Yang

Christine Huang

Yan Feng

Praveen Aanur

Joseph E Myers

Maria Rodriguez

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

Antibodies against CD73 and uses thereof

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)

Provided herein are heavy chain constant regions (referred to as 'modified heavy chain constant regions'), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.

Antibodies comprising modified heavy constant regions

Antibodies against CD73

The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.

Growing community of inventors

Hillsborough, NJ, United States of America

Sandra V Hatcher